Max-Planck-Institute of Psychiatry
22
4
4
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
9.1%
2 terminated/withdrawn out of 22 trials
86.7%
+0.2% vs industry average
18%
4 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
VR Pupillometry in Cognitive Impairment
Role: lead
IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition
Role: lead
Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in Depression
Role: lead
Effects of Schema Therapy vs. Cognitive Behavioral Therapy vs. Individual Supportive Therapy
Role: lead
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
Role: lead
Initial Effect Size Estimation of a Smartwatch-based Intervention for Physical and Behavioral Activation in Depressed Patients
Role: lead
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
Role: lead
Biological Classification of Mental Disorders
Role: lead
Multimodal Biomarkers of Electroconvulsive Therapy in Severe and Treatment-resistant Depression
Role: lead
Investigating Differential Effects of Online Mental Training Interventions on Mental Well-being and Social Cohesion
Role: collaborator
Observational Study on Metabolism and Psychopathology in Transsexual Patients
Role: lead
Evaluation of an Intensive Inpatient Psychotherapy Treatment for Severely and Early Traumatized Children (MOSES)
Role: collaborator
Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene
Role: lead
Hormone Treatment in Growth Hormone and Testosterone Deficient Patients
Role: lead
Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency
Role: lead
Venlafaxine Augmentation in Treatment Resistant Depression
Role: lead
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
Role: collaborator
Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism
Role: lead
Short-term Metabolic Effects of Mirtazapine in Healthy Subjects
Role: lead
DETECT-Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment
Role: collaborator